Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-23-016262
Filing Date
2023-05-01
Accepted
2023-05-01 16:21:22
Documents
20

Document Format Files

Seq Description Document Type Size
1 DEF 14A ntla-20230428.htm   iXBRL DEF 14A 2723692
2 GRAPHIC img109051035_0.jpg GRAPHIC 28853
3 GRAPHIC img109051035_1.jpg GRAPHIC 28853
4 GRAPHIC img109051035_2.jpg GRAPHIC 41061
5 GRAPHIC img109051035_3.jpg GRAPHIC 161866
6 GRAPHIC img109051035_4.jpg GRAPHIC 529239
7 GRAPHIC img109051035_5.jpg GRAPHIC 195418
  Complete submission text file 0000950170-23-016262.txt   6029927

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ntla-20230428_pre.xml EX-101.PRE 6716
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ntla-20230428_lab.xml EX-101.LAB 11388
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ntla-20230428_def.xml EX-101.DEF 5119
11 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ntla-20230428.xsd EX-101.SCH 4868
14 EXTRACTED XBRL INSTANCE DOCUMENT ntla-20230428_htm.xml XML 347714
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

EIN.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37766 | Film No.: 23873993
SIC: 2835 In Vitro & In Vivo Diagnostic Substances